Krystal Biotech Files Response With USPTO On KB801 Patent Application
KRYS•USPTO response and KB801 trial update
July 21 (Reuters) - Krystal Biotech Inc KRYS.O:
- Krystal Biotech files response with USPTO on KB801 patent application - SEC filing
- Krystal Biotech discontinues clinical study to advance KB801 into pivotal trial; no safety concerns observed - SEC filing
- Krystal Biotech says there will be no further subject-level updates from the discontinued study; pivotal trial results are expected in due course - SEC filing
Source text: [ID:n0001711279-26-000050]
Further company coverage: KRYS.O
